Page last updated: 2024-09-05

tbc-11251 and Chemical and Drug Induced Liver Injury, Chronic

tbc-11251 has been researched along with Chemical and Drug Induced Liver Injury, Chronic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cross, DM; Derzi, M; Horsley, E; Owen, K; Stavros, FL1

Other Studies

1 other study(ies) available for tbc-11251 and Chemical and Drug Induced Liver Injury, Chronic

ArticleYear
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (ThelinĀ®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
    Regulatory toxicology and pharmacology : RTP, 2012, Volume: 64, Issue:1

    Topics: Alkaline Phosphatase; Animals; Antihypertensive Agents; Blood Coagulation; Carcinogenicity Tests; Carcinogens; Chemical and Drug Induced Liver Injury, Chronic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Erythrocyte Indices; Female; Hypertension, Pulmonary; Hypertrophy; Isoxazoles; Liver; Liver Function Tests; Male; Mice; Mice, Inbred Strains; Organ Size; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Thiophenes

2012